Elzasonan
Depressive and anxiety disorders
- CAS No.
- 361343-19-3
- Indication Class
- CNS / Psychiatry
- Patent Expiry
- Off-patent · 2020 (to verify)
- Therapeutic Area
- Psychiatry / Neurology
- Target / Mechanism
- HTR1B·HTR1D
- Labeled Purity
- 98%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- API (Commercialized)
- Linked Intermediates
- Confirm per inquiry
- Patent Scope
- 2000s compound patent; expired per 20-yr term estimate — to be verified
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higherNo intermediate entries are on file for this API yet. You can still enquire by CAS number — we will route it to the supply side for manual sourcing.
Listing Logic · Why It's Worth Listing
An NK1-receptor-route candidate for mood disorders; psychiatric drugs have long cycles and rigid demand, offering differentiated mechanistic value.
Psychiatry / Neurology · Marketed; available for immediate sourcing
GMP/DMF-ready; supports regulatory filing and audit in target markets
Intermediates confirmed per inquiry
Product Description
Elzasonan is an investigational drug designed to enhance serotonin signaling in the brain through selective blockade of 5-HT1B and 5-HT1D autoreceptors. It has been studied for the potential treatment of major depressive disorder (MDD).
Supply source: Unibest · Elzasonan, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.